Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2017, Pages

  Schuetz, Philipp ^a,b   Wirz, Yannick ^a   Sager, Ramon ^a   Christ Crain, Mirjam ^c   Stolz, Daiana ^c   Tamm, Michael ^c   Bouadma, Lila ^d   Luyt, Charles E ^e   Wolff, Michel ^f   Chastre, Jean ^g   Tubach, Florence ^g   Kristoffersen, Kristina B ^h   Burkhardt, Olaf ⁱ   Welte, Tobias ^i,j   Schroeder, Stefan ^k   Nobre, Vandack ^l   Wei, Long ^m   Bucher, Heiner C ^n,o   Bhatnagar, Neera ^p   Annane, Djillali ^q   Reinhart, Konrad ^r   Branche, Angela ^s   Damas, Pierre ^t   Nijsten, Maarten ^u   de Lange, Dylan W ^v   Deliberato, Rodrigo O ^w   Lima, Stella Ss ^l   Maravić Stojković, Vera ^x   Verduri, Alessia ^y   Cao, Bin ^z   Shehabi, Yahya ^aa,ab   Beishuizen, Albertus ^ac   Jensen, Jens Ulrik S ^ad,ae   Corti, Caspar ^ae   Van Oers, Jos A ^af   Falsey, Ann R ^s   de Jong, Evelien ^ag   Oliveira, Carolina F ^l   Beghe, Bianca ^y   Briel, Matthias ^b,o   Mueller, Beat ^a,b   more..

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d BICHAT HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j German Center for Lung Research   (Germany)

^k Department of Anesthesiology and Intensive Care Medicine   (Germany)

^l FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^m SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

ⁿ UNIVERSITY OF BASEL   (Switzerland)

^o UNIVERSITY HOSPITAL BASEL   (Switzerland)

^p MCMASTER UNIVERSITY   (Canada)

^q RAYMOND POINCARÉ HOSPITAL   (France)

^r JENA UNIVERSITY HOSPITAL   (Germany)

^s UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^t UNIVERSITY OF LIÈGE   (Belgium)

^u UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^v UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^w HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^x Dedinje Cardiovascular Institute   (Serbia)

^y UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^z CAPITAL MEDICAL UNIVERSITY   (China)

^aa SOUTHERN HEALTH   (Australia)

^ab MONASH UNIVERSITY   (Australia)

^ac MEDISCH SPECTRUM TWENTE   (Netherlands)

^ad UNIVERSITY OF COPENHAGEN   (Denmark)

^ae Mental Health Services CPH   (Denmark)

^af CPRLab   (Netherlands)

^ag VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; PLACEBO; PRISTINAMYCIN; PROCALCITONIN; SODIUM SELENITE; TOBRAMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; PROTEIN PRECURSOR;

ALL CAUSE MORTALITY; ANTIBIOTIC THERAPY; ASTHMA; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMON COLD; COMMUNITY ACQUIRED PNEUMONIA; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG USE; FOLLOW UP; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; META ANALYSIS; MORTALITY; OTITIS MEDIA; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; RHINOSINUSITIS; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; TONSILLITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; ACUTE DISEASE; BACTERIAL INFECTION; BLOOD; CAUSE OF DEATH; TREATMENT FAILURE;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOMARKERS; CALCITONIN; CALCITONIN GENE-RELATED PEPTIDE; CAUSE OF DEATH; HUMANS; PROTEIN PRECURSORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; TREATMENT FAILURE;

EID: 85030988934     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007498.pub3     Document Type: Review

References (104)

1. Annane D, Maxime V, Faller JP, Mezher C, Clec'h C, Martel P, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open 2013;3(2):pii: e002186. 6761978
2. Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Internal Medicine 2016;176(9):1266-76. 6761980
3. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375(9713):463-74. 2975454
4. Branche AR, Walsh EE, Vargas R, Hulbert B, Formica MA, Baran A, et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. Journal of Infectious Diseases 2015;212(11):1692-700. 6761982
5. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Archives of Internal Medicine 2008;168(18):2000-7. 2975456
6. Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. European Respiratory Journal 2010;36(3):601-7. 2975458
7. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay M, Huber P, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;1363(9409):600-7. 2975460
8. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2006;174(1):84-93. 2975462
9. Corti C, Fally M, Fabricius-Bjerre A, Mortensen K, Jensen BN, Andreassen HF, et al. Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. International Journal of Chronic Obstructructive Pulmonary Disease 2016;11:1381-9. [DOI: 10.2147/COPD.S104051]6761984
10. De Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infectious Diseases 2016;16(7):819-27. 6761986
11. Deliberato RO, Marra AR, Sanches PR, Martino MD, Ferreira CE, Pasternak J, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagnostic Microbiology and Infectious Disease 2013;76(3):266-71. 6761988
12. Ding J, Chen Z, Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. International Journal of Medical Sciences 2013;10(7):903-7. 6761990
13. Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care 2009;13(3):R83. 2975464
14. Kristoffersen KB, Sogaard OS, Wejse C, Black FT, Greve T, Tarp B, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission - a randomized trial. Clinical Microbiology and Infection 2009;15(5):481-7. 2975466
15. Layios N, Lambermont B, Canivet JL, Morimont P, Preiser JC, Garweg C, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine 2012;40(8):2304-9. 6761992
16. Lima SS, Nobre V, de Castro Romanelli RM, Clemente WT, da Silva Bittencourt HN, Melo AC, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Annals of Hematology 2016;95(7):1169-76. 6761994
17. Long W, Deng XQ, Tang JG, Xie J, Zhang YC, Zhang Y, et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community acquired pneumonia. Zhonghua Nei Ke Za Zhi 2009;48(3):216-9. 2975468
18. Long W, Deng X, Zhang Y, Lu G, Xie J, Tang J. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community acquired pneumonia. Respirology 2011;76(1):266-9. 2975470
19. Long W, Li LJ, Huang GZ, Zhang XM, Zhang YC, Tang JG, et al. Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up. Critical Care 2014;18(5):471. 6761996
20. Maravić-Stojković V, Laušević-Vuk L, Jović M, Ranković A, Borzanović M, Marinković J. Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv Celokupno Lekarstvo 2011;139(11-12):736-42. 6761997
21. Najafi A, Khodadadian A, Sanatkar M, Shariat Moharari R, Etezadi F, Ahmadi A, et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Medica Iranica 2015;53(9):562-7. 6761999
22. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2009;177(5):498-505. 2975472
23. Ogasawara T, Umezawa H, Naito Y, Takeuchi T, Kato S, Yano T, et al. Procalcitonin-guided antibiotic therapy in aspiration pneumonia and an assessment of the continuation of oral intake. Respiratory Investigation 2014;52(2):107-13. 6762001
24. Oliveira CF, Botoni FA, Oliveira CR, Silva CB, Pereira HA, Serufo JC, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Critical Care Medicine 2013;41(10):2336-43. 6762003
25. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Archives of Surgery 2009;394(2):221-6. 2975474
26. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009;302(10):1059-66. 2975476
27. Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. ProGUARD Study Investigators, ANZICS Clinical Trials Group. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2014;190(10):1102-10. 6762005
28. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131(1):9-19. 2975478
29. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. European Respiratory Journal 2009;34(6):1364-75. 2975480
30. Tang J, Long W, Yan L, Zhang Y, Xie J, Lu G, et al. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infectious Diseases 2013;13:596. [DOI: 10.1186/1471-2334-13-596]6762007
31. Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, Liverani A, et al. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS ONE 2015;10(3):e0118241. 6762009
32. Wang JX, Zhang SM, Li XH, Zhang Y, Xu ZY, Cao B. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. International Journal of Infectious Diseases 2016;48:40-5. [DOI: 10.1016/j.ijid.2016.04.024]6762011
33. Dharaniyadewi D, Lie KC, Sukmana N, Rumende CM. Effect of semi-quantitative procalcitonin assay on the adequacy of empirical antibiotics and mortality in septic patients. Citical Care 2013;17(Suppl 4):P15. 6762013
34. Esposito S, Tagliabue C, Picciolli I, Semino M, Sabatini C, Consolo S, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respiratory Medicine 2011;105(12):1939-45. 2975482
35. Heyland DK, Johnson AP, Reynolds SC, Muscedere J. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Critical Care Medicine 2011;39(7):1792-9. 2975484
36. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Critical Care Medicine 2011;39(9):2048-58. 2975486
37. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Annals of Emergency Medicine 2007;50(1):34-41. 2975488
38. Kook JL, Chao SR, Le J, Robinson PA. Impact of the use of procalcitonin assay in hospitalised patients with pneumonia at a community care hospital. Infection Control and Hospital Epidemiology 2012;33(4):424-6. 2975490
39. Liew YX, Chlebicki MP, Lee W, Hsu LY, Kwa AL. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP). European Journal of Clinical Microbiology and Infectious Diseases 2011;30:853-5. 2975492
40. Liu BH, Li HF, Lei Y, Zhao SX, Sun ML. Clinical significance of dynamic monitoring of procalcitonin in guiding the use of antibiotics in patients with sepsis in ICU. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013;25(11):690-3. 6762015
41. Qu R, Ji Y, Ling Y, Ye CY, Yang SM, Liu YY, et al. Procalcitonin is a good tool to guide duration of antibiotic therapy in patients with severe acute pancreatitis. A randomized prospective single-center controlled trial. Saudi Medical Journal 2012;33(4):382-7. 2975496
42. Saeed K, Dryden M, Bourne S, Paget C, Proud A. Reduction in antibiotic use through procalcitonin testing in patients in the medical admission unit or intensive care unit with suspicion of infection. Journal of Hospital Infection 2011;78(4):289-92. 2975498
43. Schuetz P, Batschwaroff M, Dusemund F, Albrich W, Burgi U, Maurer M, et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. European Journal of Clinical Microbiology and Infectious Diseases 2010;29(3):269-77. 2975500
44. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clinical Trials 2005;2(3):209-17. 2975502
45. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clinical Infectious Diseases 2004;39(2):206-17. 2975504
46. Stocker M, Fontana M, el Helou S, Wegscheider K, Berger TM. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 2010;97(2):165-74. 2975506
47. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infectious Diseases 2007;7(3):210-7. 2975508
48. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37(6):497-507. 2975510
49. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Critical Care Medicine 2006;34(7):1996-2003. 2975512
50. NCT02130986. Procalcitonin Antibiotic Consensus Trial (ProACT). clinicaltrials.gov/ct2/show/study/NCT02130986 First received: May 1, 2014. 6762017
51. NCT02261610. Pulmonary Embolism and PCT. PE-PCT Study. clinicaltrials.gov/ct2/show/NCT02261610 First received: September 5, 2014. 6762019
52. NCT02332577. Study to compare the efficacy of pristinamycin (Pyostacine) versus amoxicillin in the treatment of acute community acquired pneumonia. clinicaltrials.gov/ct2/show/NCT02332577 First received: January 5, 2015. 6762021
53. NCT02440828. Addition of tobramycin inhalation in the treatment of ventilator associated pneumonia (VAPORISE). clinicaltrials.gov/ct2/show/NCT02440828 First received: March 13, 2015. 6762023
54. NCT02787603. Procalcitonin in Early Antibiotic Interruption in Patient With Bacterial Pulmonary infeCtion and Acute Heart Failure (EPICAD). clinicaltrials.gov/ct2/show/NCT02787603 First received: May 25, 2016. 6762025
55. NCT02862314. PROcalcitonin Pneumonia/Pneumonitis Associated With ASPIration (PROPASPI). clinicaltrials.gov/ct2/show/NCT02862314 First received: July 29, 2016. 6762027
56. NCT02931409. Intraoperative PEEP optimization: effects on postoperative pulmonary complications and inflammatory response. clinicaltrials.gov/ct2/show/NCT02931409 First received: October 5, 2016. 6762029
57. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life": an international, multicenter post-study survey (ProREAL). Archives of Internal Medicine 2012;172(9):715-22.
58. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003539.pub2]
59. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
60. Balk RA, Kadri SS, Cao Z, Robinson SB, Lipkin C, Bozzette SA. Effect of procalcitonin testing on health-care utilization and costs in critically ill patients in the United States. Chest 2017;151(1):23-33.
61. Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ 2009;338:b1374.
62. Doan Q, Enarson P, Kissoon N, Klassen TP, Johnson DW. Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD006452.pub4]
63. Drozdov D, Schwarz S, Kutz A, Grolimund E, Rast AC, Steiner D, et al. Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Medicine 2015;13(1):104.
64. Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 2002;359(9318):1648-54.
65. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278(11):901-4.
66. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365(9435):579-87.
67. GRADE Working Group, McMaster University. GRADEpro GDT. Version (accessed April 2017). Hamilton (ON): GRADE Working Group, McMaster University, 2014.
68. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
69. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
70. Hoare Z, Lim WS. Pneumonia: update on diagnosis and management. BMJ 2006;332(7549):1077-9.
71. Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clinical Microbiology and Infection 2015;21(5):474-81.
72. Konstantinides S. Clinical practice. Acute pulmonary embolism. New England Journal of Medicine 2008;359(26):2804-13.
73. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine 2006;34(6):1589-96.
74. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136(5):1237-48.
75. Kutz A, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Critical Care (London, England) 2015;19(1):74.
76. Kutz K, Hausfater P, Oppert M, Alan M, Grolimund E, Gast C, et al. Comparison between B·R·A·H·M·S PCT direct, a new sensitive point-of-care testing device for rapid quantification of procalcitonin in emergency department patients and established reference methods - a prospective multinational trial. Clinical Chemistry and Laboratory Medicine 2016;54(4):577-84.
77. Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit: advances and obstacles. American Journal of Respiratory and Critical Care Medicine 2009;179(6):434-8.
78. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009;62(10):e1-34.
79. Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD000022.pub3]
80. Manzano S, Bailey B, Girodias JB, Galetto-Lacour A, Cousineau J, Delvin E. Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. American Journal of Emergency Medicine 2010;28(6):647-53.
81. Meili M, Muller B, Kulkarni P, Schutz P. Management of patients with respiratory infections in primary care: procalcitonin, C-reactive protein or both?. Expert Review of Respiratory Medicine 2015;9(5):587-601.
82. Meili M, Kutz A, Briel M, Christ-Crain M, Bucher HC, Mueller B, et al. Infection biomarkers in primary care patients with acute respiratory tract infections - comparison of procalcitonin and C-reactive protein. BMC Pulmonary Medicine 2016;16(1):43.
83. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Critical Care Medicine 2000;28(4):977-83.
84. Muller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Medical Weekly 2001;131(41-2):595-602.
85. Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010;138(1):121-9.
86. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
87. Sager R, Kutz A, Mueller B, Schuetz P. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Medicine 2017;15(1):15.
88. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine 2011;171(15):1322-31.
89. Schuetz P, Aujesky D, Muller C, Muller B. Biomarker-guided personalised emergency medicine for all - hope for another hype?. Swiss Medical Weekly 2015;145:w14079.
90. Schuetz P, Daniels LB, Kulkarni P, Anker SD, Mueller B. Procalcitonin: a new biomarker for the cardiologist. International Journal of Cardiology 2016;223:390-7. [DOI: 10.1016/j.ijcard.2016.08.204]
91. Schuetz P, Birkhahn R, Sherwin R, Jones AE, Singer A, Kline JA, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin monitoring sepsis (MOSES) study. Critical Care Medicine 2017;45(5):781-9.
92. Spurling GKP, Del Mar CB, Dooley L, Foxlee R. Delayed antibiotics for respiratory infections. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD004417.pub3]
93. StataCorp LP. Stata Statistical Software: Release 12.1. College Station (TX): StataCorp LP, 2005.
94. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA 2015;313(16):1657-65.
95. Stojanovic I, Schneider JE, Wei L, Hong Z, Keane C, Schuetz P. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective. Clinical Chemistry and Laboratory Medicine 2017;55(4):561-70.
96. Thompson SG, Turner RM, Warn DE. Multilevel models for meta-analysis, and their application to absolute risk differences. Statistical Methods in Medical Research 2001;10(6):375-92.
97. Turner RM, Omar RZ, Yang M, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2000;19(24):3417-32.
98. van Vugt SF, Broekhuizen BD, Lammens C, Zuithoff NP, de Jong PA, Coenen S, et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ 2013;346:f2450.
99. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infectious Diseases 2013;13(5):426-35.
100. Zaas AK, Garner BH, Tsalik EL, Burke T, Woods CW, Ginsburg GS. The current epidemiology and clinical decisions surrounding acute respiratory infections. Trends in Molecular Medicine 2014;20(10):579-88.
101. Schuetz P, Briel M, Christ-Crain M, Wolbers M, Stolz D, Tamm M, et al. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2008, Issue 10. [DOI: 10.1002/14651858.CD007498]
102. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Review of Anti-Infective Therapy 2010;8(5):575-87.
103. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine 2011;171(15):1322-31.
104. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD007498.pub2]